S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000821404.03661.11 |
| _version_ | 1797283203212378112 |
|---|---|
| author | M Telen S Saraf K Cruz M Idowu T Kalfa I Osunkwo R Hagar J Geib S Forsyth P Schroeder E Wu P Kelly R Brown |
| author_facet | M Telen S Saraf K Cruz M Idowu T Kalfa I Osunkwo R Hagar J Geib S Forsyth P Schroeder E Wu P Kelly R Brown |
| author_sort | M Telen |
| collection | DOAJ |
| first_indexed | 2024-03-07T17:27:40Z |
| format | Article |
| id | doaj.art-e98bbfbbe10b4d8984f41586c83cad03 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:27:40Z |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-e98bbfbbe10b4d8984f41586c83cad032024-03-02T18:51:38ZengWileyHemaSphere2572-92412022-01-0165510.1097/01.HS9.0000821404.03661.11202201001-00010S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKSM Telen0S Saraf1K Cruz2M Idowu3T Kalfa4I Osunkwo5R Hagar6J Geib7S Forsyth8P Schroeder9E Wu10P Kelly11R Brown121 Duke University, Durham, UNITED STATES2 University of Illinois, Chicago, UNITED STATES3 Advanced Pharma, Miami, UNITED STATES4 Memorial Hermann-Texas Medical Center, Houston, UNITED STATES5 Cincinnati Children’s Hospital Medical Center, Cincinnati, UNITED STATES6 Levine Cancer Institute, Atrium Health, Charlotte, UNITED STATES7 UCSF Benioff Children’s Hospital San Francisco, Oakland, UNITED STATES8 Forma Therapeutics, Inc, Watertown, UNITED STATES8 Forma Therapeutics, Inc, Watertown, UNITED STATES8 Forma Therapeutics, Inc, Watertown, UNITED STATES8 Forma Therapeutics, Inc, Watertown, UNITED STATES8 Forma Therapeutics, Inc, Watertown, UNITED STATES9 Children’s Healthcare of Atlanta, Atlanta, UNITED STATEShttp://journals.lww.com/10.1097/01.HS9.0000821404.03661.11 |
| spellingShingle | M Telen S Saraf K Cruz M Idowu T Kalfa I Osunkwo R Hagar J Geib S Forsyth P Schroeder E Wu P Kelly R Brown S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS HemaSphere |
| title | S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS |
| title_full | S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS |
| title_fullStr | S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS |
| title_full_unstemmed | S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS |
| title_short | S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS |
| title_sort | s109 activation of pyruvate kinase r with etavopivat ft 4202 is well tolerated improves anemia and decreases intravascular hemolysis in patients with sickle cell disease treated for up to 12 weeks |
| url | http://journals.lww.com/10.1097/01.HS9.0000821404.03661.11 |
| work_keys_str_mv | AT mtelen s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks AT ssaraf s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks AT kcruz s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks AT midowu s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks AT tkalfa s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks AT iosunkwo s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks AT rhagar s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks AT jgeib s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks AT sforsyth s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks AT pschroeder s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks AT ewu s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks AT pkelly s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks AT rbrown s109activationofpyruvatekinaserwithetavopivatft4202iswelltoleratedimprovesanemiaanddecreasesintravascularhemolysisinpatientswithsicklecelldiseasetreatedforupto12weeks |